PDF电子书：分子疗法（2011）

tianzhang

; I' T% r* r' ^% U
1 l2 |( [" L) A" y) W7 M' KMolecular therapies, S/ S6 j7 _0 ~! y9 t+ k( G
Dr. Zoltán Balajthy, Dr. János Aradi, Dr. Zoltán Balajthy, Dr. Éva Csősz, Dr. Beáta Scholtz, Dr. István Szatmári, Dr. József Tőzsér, Dr. Tamás Varga (2011)
8 e7 h) r/ H8 P6 P. f6 v
. \) n3 j. y% L$ c, @. R. YUniversity of Debrecen
  I2 t0 R4 Q% p' ?' F0 j1 q# DCopyright © 2011 The project is funded by the European Union and co-financed by the European Social Fund., Manuscript completed: 17 November 2011
) p# Q$ A( \3 h9 v9 G& D! |, S
4 w% l9 Y. k$ g% v: U3 z" q9 }( I( a5 O( j9 O) F

* [2 Y! |6 e3 K" zIndex) n; f1 V) S9 A  I, C
1. 1. Functional Genomics" s% z' N# l- @6 c2 y
1.1 Definitions
0 |  J" B( x+ q9 E8 A1.2 About diseases
% _( @+ M; N+ }6 P' t1.3 Approaches to understanding disease mechanisms  v& j1 N( v& p, r& @
1.3.1 Gene expression is regulated in several basic ways
: ^$ Y: Y( R) R' P& S" x1.3.2 Microarrays: functional genomics in cancer research
+ o+ K9 f' L; i9 C8 x" m2 b9 _1.3.3 A Variety of Genetic Alterations Underlie Developmental Abnormalities and Disease
& d: [& ?0 d; J; Z# _9 [6 X: n1.3.4 Genomic microarrays( ?0 y& D' K7 |$ g- L/ `
2. 2. Recombinant proteins
# c9 @+ h4 B( [2 ]. [" {# b2.1 Overview: Protein pharmaceuticals
# ]7 l' V0 w" @+ x$ e( {5 Y2.2 Cell-free systems: In vitro transcription and translation
6 l( [4 o4 e1 i& x1 }2.3 Recombinant protein expression in isolated cells (cell culture)/ Q7 P* V% B( a6 v' v, K
2.4 Non-prokaryotic expression systems4 X* @! K7 C; T' [3 N# M
2.4.1 Cloning in Pichia pastoris
6 d, n; R8 E( A1 w4 H* |2.4.2 Baculovirus mediated protein expression in insect cells" a8 V" }! C* U8 M8 ^; p# c. |
2.4.3 Mammalian expression systems/ _/ X  q) g& v( ~" I. C
2.5 Purification of recombinant proteins4 N; t, S3 _9 V# r4 ?: h+ V
3. 3. Gene Therapy: Vectors and Strategies.- Y7 g' H6 {/ V* Q" e+ V
3.1 Vectors for Gene Therapy2 F' x% G) O: ?
3.2. Types of gene transfer, vectors for gene therapy9 z( _7 n2 [2 q  X- x% w% r. R
3.3. General gene therapy strategies
$ F0 n4 Y& Q  Y; d/ I' d3.4. Human gene therapy6 D0 O! `$ V( \5 A) P
4. 4. Protein replacement therapies.
- O5 _+ k9 `% _$ M7 O5 a) S$ q5. 5. Recombinant antibodies and the phage display technology' w; D& v" u$ ~
5.1. Introduction/ B/ c4 ?) ?* ^6 u; o$ v& y9 p/ P
5.1.1. The structure of antibodies and their production in the body2 O: w0 m  o- B: {- `" X
5.1.2. Antigen-antibody binding
& W7 k' d. t0 b& D- Z6 R5.2. The production of therapeutic antibodies" B  i: N& c3 z, V3 J4 G
5.2.1. The production of antibodies in hybridoma cells.1 ]. [3 t7 O" N' F" [' o% F0 L
5.2.2. Humanized antibodies
1 A2 i) O9 O" e9 r5.2.3. Production of human antibodies
6 U$ b  C8 E8 K+ D3 k5.3. Generation of antibodies by phage display
& s! u. B6 {2 ^) F4 L; N6 @5.3.1. The phage display technology$ P7 D; P8 g% V
5.3.2. Generation of phage libraries8 y- x, B# w; ]
5.4. Administration of therapeutic antibodies8 T0 X% r3 X5 W* S; m- C% ~: o, N
6. 6. Anti-cytokine Therapy (sepsis).
; N+ C- ?2 B* C6.1. The consequences of developing inflammation( T$ [8 o8 L4 A2 Y' V7 b, n
6.2. Development of Inflammatory Response: Synthesis of Lipid Mediators$ E: y0 ]) k6 x5 u2 [% D  I, n' w
6.3. Role of the Liver in Maintenance of Homeostasis: Acute Phase Response8 F! o# s/ `3 r0 u& @3 L8 t
6.4. Time-Course of the Inflammatory Response During Sepsis0 Z. B0 n! j7 o" @( s' p, `, F* M
7. 7. Animal models and transgenesis in biotechnology
8 d% i" k- Y2 `' |$ p8. 8. Embryonic and adult stem cells in regenerative medicine I.
. \9 S) _, C* d8.1 Embryonic stem cells; ~* y3 z: s* g! H4 K- ?
8.2 Somatic cell reprogramming into pluripotent stem cells
1 r4 k3 \& G  e$ d8.3 Adult stem cells- l- N0 v* W7 o  Q4 u5 Z- M2 u6 q
9. 9. Embryonic and adult stem cells in regenerative medicine II.
& V( i8 j3 d9 Y! d6 M9 g% \9.1 Pluripotent stem cells for regenerative medicine
$ n: O4 R9 [% @9.2 Clinical application of stem cells
: ?* ~2 r* ~% X5 [+ s9.3 Stem cell therapy to cure various diseases
/ }) E6 `7 k- N+ j# Z10. 10.        Cell Cycle and Cancer Therapy, p53 I.8 D( S. s) d1 w& y! K
10.1 Cell Cycle
- s3 f8 h+ i2 z% G" g! P10.2. Mitogenic Signaling in Eukaryotic Cell Controls the Rate of Cell Division
! T6 M' w- ^" O* P+ B4 |10.3. Biochemical Events of Cell-cycle – in M Phase) g5 G" n6 @$ E+ \) e: Z9 [8 J2 @+ i; ?
10.4. Protooncogenes
5 a$ ]& A  ^. k10.5. ErbB/HER Receptors' \! ]+ L" p; F4 A9 s
10.6. Therapeutic targets
) h# R# j4 ~6 Y: a1 |; Z) R11. 11. Cell Cycle and Cancer Therapy, p53 II.1 m7 Y/ C* P5 j5 ~) b
11.1. Tumor Suppressor Genes and p53
+ a) W0 {+ i0 u11.2. Biochemical Pathways of Apoptosis and its Therapeutic Utilization) q8 q/ d2 `8 A
12. 12. Gene Silencing Technologies., Y; m+ `" Y( L, x
12.1 Introduction: \) b7 R7 F$ Z; @7 p' f4 f  e- M
12.2 Action of antisense oligonucleotides9 l8 q* r: k- r, b7 Y
12.3 Chemical modifications of gene silencing oligonucleotides; general considerations
0 z1 G. S* ~0 p12.4 Inhibition of transcription by triple helix forming oligonucleotides
; d: [* s+ f7 m12.5 Gene silencing by ribozymes* l% d; y; D" T' ^
12.6 Gene silencing with short RNA fragments
& e* s; `$ K4 c+ M" a- L12.7 Important final note. d) E0 Z. V( E; r
! D& m" s$ y# A) N% k$ k
[hide][/hide]

mzaq2006

看看

mzaq2006

无法下载啊，扣了24个包包都不行

mzaq2006

是32个包包啊

goblinwang

学习学习

goblinwang

呵呵，我可以下载，估计，你不是使用网页自带的下载吧，记得以前论坛提起，尽量不用迅雷等下载软件，你在试试吧

xylan327

谢谢分享

xuguofeng

肌源性干细胞

石头111

干细胞研究重在基础

MIYAGI

嘿嘿......哈哈......呵呵.....哟~呼